(TheNewswire)
Toronto, Ontario / TheNewswire / March 14,
2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce
that it has created a Business Advisory Committee (BAC) and has appointed Dr. Samuel Schwartz as the inaugural Chairman. The
BAC will provide senior management and the Board of Directors with strategic advice on matters including,
but not limited to, financing alternatives and opportunities, market opportunities, human resource insights, and new technology
perspectives, in addition to carrying out special assignments.
“We are very pleased to have Sam’s many years of assisting small companies to grow internationally
at our disposal,” stated Dr. George Adams, CEO of Ventripoint. “This is especially important at this time as the Company
looks at strategic approaches to growing its business.”
“I am excited to have the opportunity to bring together a world-class group to advise Ventripoint on
its goal to achieve better cardiac diagnosis and monitoring for everyone, especially children,” commented Dr. Schwartz.
Sam is the founder of The Strategic Law Group. He previously was the Managing Partner of the Toronto
office of DLA Piper Canada LLP, where he practiced in the areas of corporate/commercial, corporate finance, structuring, and
securities law, including merchant banking and public and private company transactions. His diverse client base included Canadian
and foreign companies involved in the life sciences, biotechnology, and computer hardware and software. Sam has regularly assisted
established as well as start-up companies in accessing the capital markets both in Canada and the United States. In addition, he
has assembled professional teams to assist Canadian companies in their business development efforts worldwide.
Among Sam’s community involvements, he served on The Strategic Planning Committee of the Baycrest
Centre for Geriatric Care; The National Board of Directors of the Canadian Friends of Hebrew University; The National Campaign
Cabinet of the Canadian Cancer Society; and the Board of Directors of Mount Sinai Hospital Foundation. He also served on the Board
of Governors of York University and is presently a Life Honorary Governor of the University.
Sam received his JD and LLB from Osgoode Hall Law School of York University and was called
to the Ontario Bar in 1974 and the Alberta Bar in 1978. Previously, he received an MA degree from York University and a BA degree
from the University of Toronto. In 2010, he was recognized by Osgoode Hall Law School by being awarded a Gold Key for
Outstanding Achievement. In 2015, he was awarded an Honorary Doctorate Degree from York University for Outstanding Contributions to
the Canadian Community.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has
developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac
care.
For further information, please contact:
Dr. George Adams, CEO,
Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other
factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most
recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news
release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news
release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required
by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.